When was Metabolomic Discoveries founded?

Metabolomic Discoveries was founded in 2009.

Where is Metabolomic Discoveries located?

Metabolomic Discoveries is headquartered in Potsdam, Germany.

Who is the current CEO of Metabolomic Discoveries?

Nicolas Schauer of Metabolomic Discoveries.

Is Metabolomic Discoveries a funded company?

Metabolomic Discoveries is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Metabolomic Discoveries rank among its competitors?

Metabolomic Discoveries ranks 1964th amongst 1981 active competitors, of which 458 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Metabolomic Discoveries?

Metabolomic Discoveries' top competitors include Synthego, Antheia and Transcenta. Among them, Antheia secured the most recent funding round in January, 2026.

Metabolomic Discoveries - 2026 Company Profile, Team, Funding & Competitors

Company Details

Metabolomic Discoveries provides research and analytical services. Service include high-resolution comprehensive metabolite profiling of any biological material, lipidomics and analytics. Data analysis services include statsistical amd multivariate analysis, and bioinformatics support for data integration. It also offers TagFinder , a GC-MS metabolomics software package for the analysis of GC/MS based metabolomics data and is developing Kenkodo, a metabolism based body tracking tool which is currently available in beta version.

Website: metabolomicdiscoveries.com
Social
Email ID: *****@metabolomicdiscoveries.com

Key Metrics

Founded Year

2009

Location

Potsdam, Germany

Stage

Acquired

Investors

Bmp Ventures

Ranked

1964^th among 1981 active competitors

Similar Companies

Synthego & 2691 more

Exit Details

Acquired by Metabolon (Sep 05, 2017)

View Metabolomic Discoveries' full profile

Metabolomic Discoveries got acquired by Metabolon on Sep 05, 2017.

Click here to take a look at Metabolomic Discoveries's acquisition in detail

Metabolomic Discoveries is a funded company. Metabolomic Discoveries has 1 institutional investor.

View details of Metabolomic Discoveries's funding rounds and investors

The founders of Metabolomic Discoveries is Nicolas Schauer.

Here are the details of Metabolomic Discoveries' key team members:

Nicolas Schauer: Founder & CEO of Metabolomic Discoveries.

View details of Metabolomic Discoveries's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Metabolomic Discoveries include Synthego, Antheia and Transcenta. Here is the list of Top 10 competitors of Metabolomic Discoveries, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Judges Scientific 2002, London (United Kingdom), Public	Acquisition and development of scientific instrument businesses	-	Origin Capital, Lloyds Banking Group	65/100
5th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Sino Biopharmaceutical, Orbimed & 18 others	65/100
6th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Fidelity Investments, Verition Fund Management ... & 14 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
9th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$346M	Maverick Ventures, Polaris Partners & 16 others	62/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
1964th	Metabolomic Discoveries 2009, Potsdam (Germany), Acquired	Software solutions for metabolomic data analysis	-	Bmp Ventures	19/100